Source: https://pharmj.org.ua/index.php/journal/article/view/232
Timestamp: 2019-04-22 17:56:32+00:00

Document:
Improvement of informational providing of pharmaceutical prevention care, especially in arterial hypertension, is the main direction for prevention of rational drug use. It was established that only 33% of patients with arterial hypertension control the level of arterial pressure within the limits of norm, and provision of pharmaceutical care will help to achieve the optimal level of blood pressure, increasing the persistence to the use of drugs and improve quality of life.
The aim of the work. The aim was to justify the directions of informational providing of pharmaceutical prevention care of drug prescription for arterial hypertension treatment in implementation of “Affordable Drug Program” for improving data in current provisor (pharmacist) protocol.
The study was conducted on the basis of current legislative acts approved in Ukraine and European guidelines for the treatment of arterial hypertension, as well as publications in the evidence-based basis on October 2018. The following research methods were used: systemic, analytical, content-analysis.
We analyzed the data of European recommendations 2018 (ESH/ESC) and defined new factors influencing the development of cardiovascular diseases. We also examined the evidence in drugs for prevention of arterial hypertension and the most rational choice of drugs for an individual patient, taking into consideration the concomitant status.
We reviewed as well the range of drugs for treatment of arterial hypertension, included in the regulatory lists of Ukraine that are in need of pharmaceutical prevention care. We presented the main interactions of inhibitor angiotensin II receptors. In order to improve the pharmacotherapy of patients the provisors (pharmacists) may use this information for warning about undesired interactions and side effects.
We analyzed the pharmacist protocol for prescribing of prescription drugs for treatment of people with hypertension diseases, the cost of which are partially reimbursed.
We showed that this protocol needs some basic additional information about both the primary prevention and the drugs such as angiotensin II receptor blockers and diuretics for a rational prescription and use of these medications.
The system of information support of pharmaceutists on the rational use of drugs with arterial hypertension is substantiated.
1.	Yackova G. Yu., Parnovskij B. L. Teoretichni aspekti farmacevtichnoyi profilaktiki // Farmac. zhurn. – 2006. – № 1. – S. 3‒9.
2.	Farmacevtichna enciklopediya / Golova red. radi V. P. Chernih. 2-e vid., pererob. i dopovn. ‒ K.: MORION, 2010. ‒ 1632 s.
3.	Nakaz MOZ Ukrayini vid 11. 10. 2013 r. № 875 «Protokol provizora (farmacevta) pri vidpusku za receptom likarskih zasobiv dlya likuvannya osib z gipertonichnoyu hvoroboyu, vartist yakih pidlyagaye chastkovomu vidshkoduvannyu».
13.	Aguiar P. M., Balisa-Rocha B. J. , Brito Gde C. et al. Pharmaceutical care in hypertensive patients: a systematic literature review // Res Social Adm Pharm. – 2012. – V. 8. – R. 383‒396. https://doi.org/10.1016/j.sapharm.2011.10.001.
14.	Gupta	P., Patel P., Strauch B. et al. Biochemical Screening for Nonadherence Is Associated With Blood Pressure Reduction and Improvement in Adherence // Hypertension. – 2017. – V. 70, N 5. P. – 1042‒1048.
15.	Kronish I. M., Woodward M., Sergie Z. et al. Meta-analysis: impact of drug class on adherence to antihypertensives // Circulation. – 2011. – V. 123, N 15. – P. 1611‒1621.
16.	Thomopoulos C., Parati G., Zanchetti	A. Effects of blood-pressure lowering treatment in hypertension: 9. Discontinuations for adverse events attributed to different classes of antihypertensive drugs: meta-analyses of randomized trials // J. Hypertens. – 2016. – V. 34, N 10. – P. 1921–1932.
17.	Thomopoulos C., Parati G., Zanchetti	A. Effects of blood-pressurelowering treatment on outcome incidence. 12. Effects in individuals with highnormal and normal blood pressure: overview and meta-analyses of randomized trials // J. Hypertens. – 2017. – V. 35, N 11. – P. 2150–2160.
18.	Thomopoulos C., Parati G., Zanchetti	A. Effects of blood pressurelowering on outcome incidence in hypertension: 5. Head-to-head comparisons of various classes of antihypertensive drugs - overview and meta-analyses // J. Hypertens. – 2015. – V. 33, N 7. – P. 1321–1341.
19.	Thomopoulos C., Parati G., Zanchetti	A. Effects of blood pressure lowering on outcome incidence in hypertension: 4. Effects of various classes of antihypertensive drugs-overview and meta-analyses // J. Hypertens. – 2015. – V. 33, N 2. – P. 195–211.
20.	Ettehad D., Emdin C. A., Kiran	A. et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and metaanalysis // Lancet. – 2016. – V. 387. – R. 957–967.
21.	Mancia G., Fagard R., Narkiewicz K. et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) // Eur. Heart J. – 2013. – V. 34, N 10. – P. 2159–2219.
22.	Bakris G. L., Fonseca V., Katholi R. E. et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial // JAMA. – 2004. – V. 292. – R. 2227–2236.
23.	Ayers K., Byrne L. M., DeMatteo A., Brown N. J. Differential effects of nebivolol and metoprolol on insulin sensitivity and plasminogen activator inhibitor in the metabolic syndrome // Hypertension. – 2012. – V. 59. – P. 893–898.

References: V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V.